DZ2890A1 - 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ2890A1
Authority: DZ; Algeria
Prior art keywords: carboxamino; tetrahydroquinoline; substituted; preparation; pharmaceutical compositions
Prior art date: 1998-09-17

Application number

DZ990190A

Other languages

English (en)

Inventor

Michael Paul Deninno

George Tetteh

Magnus Aryitey

Roger Benjamin Ruggeri

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2003-12-15

1999-09-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2890A1 publication Critical patent/DZ2890A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DZ990190A 1998-09-17 1999-09-13 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2890A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10086098P	1998-09-17	1998-09-17

Publications (1)

Publication Number	Publication Date
DZ2890A1 true DZ2890A1 (fr)	2003-12-15

Family

ID=22281914

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990190A DZ2890A1 (fr)	1998-09-17	1999-09-13	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (47)

Country	Link
US (4)	US6197786B1 (fr)
EP (1)	EP1114031B1 (fr)
JP (3)	JP3626685B2 (fr)
KR (1)	KR100428330B1 (fr)
CN (1)	CN1331858C (fr)
AP (1)	AP1346A (fr)
AR (1)	AR021481A1 (fr)
AT (1)	ATE297898T1 (fr)
AU (1)	AU752566B2 (fr)
BG (1)	BG65125B1 (fr)
BR (1)	BR9913810A (fr)
CA (1)	CA2344350C (fr)
CO (1)	CO5370678A1 (fr)
CR (1)	CR6310A (fr)
CU (1)	CU23082A3 (fr)
CZ (1)	CZ2001955A3 (fr)
DE (1)	DE69925845T2 (fr)
DK (1)	DK1114031T3 (fr)
DZ (1)	DZ2890A1 (fr)
EA (1)	EA004674B1 (fr)
EE (1)	EE200100166A (fr)
ES (1)	ES2243069T3 (fr)
GE (1)	GEP20033051B (fr)
GT (1)	GT199900150A (fr)
HK (1)	HK1040243A1 (fr)
HN (1)	HN1999000154A (fr)
HR (1)	HRP20010201A2 (fr)
HU (1)	HUP0103506A3 (fr)
ID (1)	ID28026A (fr)
IL (3)	IL141505A0 (fr)
IS (1)	IS5859A (fr)
MA (1)	MA26688A1 (fr)
MY (1)	MY130670A (fr)
NO (1)	NO318830B1 (fr)
NZ (1)	NZ509840A (fr)
OA (1)	OA11650A (fr)
PA (1)	PA8481401A1 (fr)
PE (1)	PE20001069A1 (fr)
PL (1)	PL347099A1 (fr)
PT (1)	PT1114031E (fr)
SK (1)	SK3542001A3 (fr)
TN (1)	TNSN99171A1 (fr)
TR (1)	TR200100768T2 (fr)
TW (1)	TWI242007B (fr)
UA (1)	UA68390C2 (fr)
WO (1)	WO2000017164A1 (fr)
YU (1)	YU16501A (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7799766B2 (en) *	1998-04-08	2010-09-21	Theta Biomedical Consulting & Development Co., Inc.	Composition for treating hormonally-dependent cancers
US20050220909A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Composition for protection against superficial vasodilator flush syndrome
US20080153761A1 (en) *	1998-04-08	2008-06-26	Theoharides Theoharis C	Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US7906153B2 (en) *	1998-04-08	2011-03-15	Theta Biomedical Consulting & Development Co., Inc.	Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) *	1998-04-08	2006-01-10	Theta Biomedical Consulting And Development Co.	Synergistic proteoglycan compositions for inflammatory conditions
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US20040230559A1 (en) *	1999-08-09	2004-11-18	Mark Newman	Information processing device and information processing method
HN2000000203A (es)	1999-11-30	2001-06-13	Pfizer Prod Inc	Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) *	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2419406A1 (fr) *	2000-08-15	2002-02-21	Pfizer Products Inc.	Combinaisons pharmaceutiques de torcetrapib et d'atorvastatine ou de derives hydroxyles pour le traitement de l'atherosclerose, de l'angine et des faibles niveaux de lipoproteinesde haute densite
US6777427B2 (en)	2000-09-14	2004-08-17	Kaken Pharmaceutical Co., Ltd.	Tetrahydroquinoline compounds
BR0209238A (pt) *	2001-04-30	2004-06-15	Pfizer Prod Inc	Compostos úteis como intermediários
EE200400024A (et) *	2001-06-21	2004-06-15	Pfizer Products Inc.	Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
WO2003000294A1 (fr)	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques contenant une dispersion solide d'un medicament peu soluble dans une matrice et d'un polymere ameliorant la solubilite
WO2003000226A2 (fr) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques contenant des ensembles polymere et medicament
WO2003000235A1 (fr) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
EP1269994A3 (fr)	2001-06-22	2003-02-12	Pfizer Products Inc.	Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
NZ529490A (en)	2001-06-22	2005-08-26	Pfizer Prod Inc	Pharmaceutical compositions of adsorbates of amorphous drug
GT200200170A (es) *	2001-09-28	2003-05-23		Preparacion de inhibidor de cetp anhidro
WO2003053359A2 (fr)	2001-12-19	2003-07-03	Atherogenics, Inc.	1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
BR0215240A (pt) *	2001-12-19	2004-10-26	Atherogenics Inc	Derivados de calcona e seu uso no tratamento de doenças
BR0307516A (pt) *	2002-02-01	2004-12-07	Pfizer Prod Inc	Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
ES2305434T3 (es)	2002-02-01	2008-11-01	Pfizer Products Inc.	Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1474144B1 (fr) *	2002-02-01	2008-08-06	Pfizer Products Inc.	Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
WO2003063822A2 (fr)	2002-02-01	2003-08-07	Pfizer Products Inc.	Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
SK2332004A3 (en)	2002-08-30	2004-12-01	Japan Tobacco Inc	Dibenzylamine compound and medicinal use thereof
US7504508B2 (en) *	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011385B1 (ru) *	2002-10-04	2009-02-27	Миллениум Фармасьютикалз, Инк.	Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004035543A1 (fr) *	2002-10-21	2004-04-29	Warner-Lambert Company Llc	Derives de tetrahydroquinoline antagonistes de crth2
WO2004056727A2 (fr) *	2002-12-19	2004-07-08	Atherogenics, Inc.	Procede de fabrication de derives de chalcone
KR20050088190A (ko) *	2002-12-20	2005-09-02	화이자 프로덕츠 인코포레이티드	콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
CA2508840A1 (fr) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Formes posologiques comprenant un inhibiteur de cetp et un inhibiteur de hmg-coa reductase
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004072046A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite des recepteurs nucleaires
WO2004072042A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite de recepteurs nucleaires
CN1761463A (zh) *	2003-03-17	2006-04-19	日本烟草产业株式会社	提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
ATE534381T1 (de) *	2003-03-17	2011-12-15	Japan Tobacco Inc	Pharmazeutische cetp-inhibitor-zusammensetzungen
JP2006520810A (ja) *	2003-03-17	2006-09-14	日本たばこ産業株式会社	Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
BRPI0410840A (pt) *	2003-05-30	2006-07-04	Ranbaxy Lab Ltd	derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
CA2532931A1 (fr) *	2003-08-04	2005-02-10	Pfizer Products Inc.	Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
BRPI0413363A (pt) *	2003-08-04	2006-10-10	Pfizer Prod Inc	formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
EP2319509A1 (fr)	2003-09-26	2011-05-11	Japan Tobacco, Inc.	Méthodes pour inhiber la production de lipoprotéines rémanents
BRPI0414671A (pt) *	2003-09-30	2006-11-21	Pfizer Prod Inc	inibidores da cetp e metabolitos dos mesmos
ES2332051T3 (es) *	2003-10-08	2010-01-25	Eli Lilly And Company	Compuestos y procedimientos para tratar dislipidemia.
CA2543596A1 (fr) *	2003-11-07	2005-05-26	Jj Pharma, Inc.	Complexes pour une therapie combinatoire stimulant les hdl
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005230915A1 (en)	2004-03-26	2005-10-20	Eli Lilly And Company	Compounds and methods for treating dyslipidemia
US7923043B2 (en) *	2004-03-30	2011-04-12	Theta Biomedical Consulting & Development Co., Inc.	Method for protecting humans against superficial vasodilator flush syndrome
MY139887A (en)	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
WO2006004903A2 (fr) *	2004-06-28	2006-01-12	Atherogenics, Inc.	1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006033001A1 (fr) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Composes de quinoline
EP2927693A1 (fr)	2004-10-06	2015-10-07	The Brigham and Women's Hospital	Pertinence de niveaux obténus de marqueurs d'inflammation géneralisée à la suite d'un traitement
KR101021828B1 (ko)	2004-10-27	2011-03-17	다이이찌 산쿄 가부시키가이샤	2 이상의 치환기를 갖는 벤젠 화합물
CA2590533C (fr) *	2004-11-23	2010-09-07	Warner-Lambert Company Llc	Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
WO2006069162A1 (fr)	2004-12-20	2006-06-29	Reddy Us Therapeutics, Inc.	Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
US8617604B2 (en)	2005-02-03	2013-12-31	Bend Research, Inc.	Pharmaceutical compositions with enhanced performance
EP1861372A1 (fr) *	2005-02-24	2007-12-05	Millennium Pharmaceuticals, Inc.	Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2006098394A1 (fr) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
JP2009514851A (ja) *	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
PE20071025A1 (es) *	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
AR059838A1 (es) *	2006-03-14	2008-04-30	Ranbaxy Lab Ltd	Formulaciones para dosis estabilizantes de estatina
TW200808731A (en) *	2006-03-30	2008-02-16	Tanabe Seiyaku Co	A process for preparing tetrahydroquinoline derivatives
US20100029716A1 (en) *	2006-04-10	2010-02-04	Concert Pharmaceuticals, Inc.	Novel 1,2,3,4- tetrahydroquinoline derivatives
MX2009000439A (es) *	2006-07-14	2009-02-04	Ranbaxy Lab Ltd	Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
ITMI20062254A1 (it) *	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
ATE547394T1 (de)	2006-12-01	2012-03-15	Bristol Myers Squibb Co	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CL2008000684A1 (es)	2007-03-09	2008-08-01	Indigene Pharmaceuticals Inc	Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
US8759383B2 (en)	2007-03-16	2014-06-24	Concert Pharmaceuticals, Inc.	Inhibitors of cholesterol ester transfer protein
CN101679309B (zh)	2007-04-13	2012-02-29	兴和株式会社	具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
JP4846769B2 (ja) *	2007-07-30	2011-12-28	田辺三菱製薬株式会社	医薬組成物
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
AU2010247391A1 (en)	2009-05-15	2011-12-01	Novartis Ag	Benzoxazolone derivatives as aldosterone synthase inhibitors
SG175925A1 (en)	2009-05-15	2011-12-29	Novartis Ag	Aryl pyridine as aldosterone synthase inhibitors
EP2435402B1 (fr)	2009-05-28	2016-04-13	Novartis AG	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
BRPI1011657A2 (pt)	2009-05-28	2019-04-16	Novartis Ag	derivados aminopropiônicos substituídos como inibidores de neprilisina
AR077208A1 (es)	2009-06-30	2011-08-10	Lilly Co Eli	Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US9050275B2 (en) *	2009-08-03	2015-06-09	Theta Biomedical Consulting & Development Co., Inc.	Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) *	2009-08-03	2015-11-03	Theta Biomedical Consulting & Development Co., Inc.	Methods of treating autism spectrum disorders and compositions for same
WO2011061168A1 (fr)	2009-11-17	2011-05-26	Novartis Ag	Dérivés d'aryl-pyridine en tant qu'inhibiteurs d'aldostérone synthase
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en)	2009-11-30	2013-11-05	Novartis Ag	Imidazole derivatives as aldosterone synthase inhibitors
MA34007B1 (fr)	2010-02-19	2013-02-01	Boehringer Ingelheim Int	Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
CA2799708A1 (fr)	2010-05-21	2011-11-24	Pfizer Inc.	2-phenylbenzoylamides
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2648788T3 (es)	2011-01-26	2018-01-08	Inserm - Institut National De La Santé Et De La Recherche Médicale	Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
WO2012110599A1 (fr)	2011-02-17	2012-08-23	Boehringer Ingelheim International Gmbh	Dérivés de pyridine tricyclique, médicaments contenant de tels composés, leur utilisation et l'un de leurs procédés de synthèse
JP2014513923A (ja)	2011-03-04	2014-06-19	ファイザー・インク	Ｅｄｎ３様ペプチドおよびその使用
TWI537262B (zh) *	2011-08-17	2016-06-11	美國禮來大藥廠	供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
US9150583B2 (en)	2011-08-17	2015-10-06	Boehringer Ingelheim International Gmbh	Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
EP2789347A4 (fr)	2011-11-29	2015-12-16	Kowa Co	Agent destiné à inhiber l'expression de l'arnm de npc1l1 et/ou de lipg et agent destiné à prévenir et/ou traiter l'obésité
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en)	2013-02-14	2015-08-28	Novartis Ag	Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
MX2015014666A (es)	2013-04-17	2016-03-01	Pfizer	Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
SG11201600211XA (en)	2013-07-25	2016-02-26	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
TW201518323A (zh)	2013-07-25	2015-05-16	Novartis Ag	合成ａｐｅｌｉｎ多肽之生物結合物
WO2016016157A1 (fr)	2014-07-30	2016-02-04	F. Hoffmann-La Roche Ag	Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl
HRP20221061T1 (hr)	2014-08-12	2022-11-25	Newamsterdam Pharma B.V.	Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrokinolinskih derivata
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
AU2016209968B2 (en)	2015-01-23	2018-11-29	Novartis Ag	Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
DK3911648T3 (da)	2019-01-18	2025-01-13	Astrazeneca Ab	6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en)	2023-05-24	2024-11-28	Novartis Ag	Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231402A (en) *	1985-04-02	1993-07-27	Telefunken Systemtechnik Gmbh	Method for detecting and classifying helicopters
US5231102A (en)	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
DE69029668T2 (de) *	1989-03-08	1997-08-07	Merck Sharp & Dohme	Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) *	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
KR920014799A (ko)	1991-01-18	1992-08-25	나오가따 다이도	신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en)	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
HRP970330B1 (en)	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
US6170342B1 (en) *	1997-05-19	2001-01-09	Particle Science	Spiral sampler
GT199900147A (es)	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en)	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en)	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000038722A1 (fr)	1998-12-23	2000-07-06	G.D. Searle & Co.	COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES
BR0209238A (pt) *	2001-04-30	2004-06-15	Pfizer Prod Inc	Compostos úteis como intermediários

1999
- 1999-09-07 US US09/391,152 patent/US6197786B1/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481401A patent/PA8481401A1/es unknown
- 1999-09-09 HN HN1999000154A patent/HN1999000154A/es unknown
- 1999-09-10 ES ES99940424T patent/ES2243069T3/es not_active Expired - Lifetime
- 1999-09-10 PT PT99940424T patent/PT1114031E/pt unknown
- 1999-09-10 YU YU16501A patent/YU16501A/sh unknown
- 1999-09-10 IL IL14150599A patent/IL141505A0/xx not_active IP Right Cessation
- 1999-09-10 CA CA002344350A patent/CA2344350C/fr not_active Expired - Fee Related
- 1999-09-10 TR TR2001/00768T patent/TR200100768T2/xx unknown
- 1999-09-10 AR ARP990104555A patent/AR021481A1/es active IP Right Grant
- 1999-09-10 AT AT99940424T patent/ATE297898T1/de not_active IP Right Cessation
- 1999-09-10 CZ CZ2001955A patent/CZ2001955A3/cs unknown
- 1999-09-10 MY MYPI99003917A patent/MY130670A/en unknown
- 1999-09-10 WO PCT/IB1999/001532 patent/WO2000017164A1/fr not_active Ceased
- 1999-09-10 ID IDW20010622A patent/ID28026A/id unknown
- 1999-09-10 CN CNB998110523A patent/CN1331858C/zh not_active Expired - Fee Related
- 1999-09-10 PL PL99347099A patent/PL347099A1/xx not_active Application Discontinuation
- 1999-09-10 JP JP2000574074A patent/JP3626685B2/ja not_active Expired - Fee Related
- 1999-09-10 CO CO99057642A patent/CO5370678A1/es not_active Application Discontinuation
- 1999-09-10 GT GT199900150A patent/GT199900150A/es unknown
- 1999-09-10 HK HK02101439.5A patent/HK1040243A1/zh unknown
- 1999-09-10 TW TW088115687A patent/TWI242007B/zh not_active IP Right Cessation
- 1999-09-10 NZ NZ509840A patent/NZ509840A/xx unknown
- 1999-09-10 PE PE1999000921A patent/PE20001069A1/es not_active Application Discontinuation
- 1999-09-10 HU HU0103506A patent/HUP0103506A3/hu unknown
- 1999-09-10 AP APAP/P/2001/002101A patent/AP1346A/en active
- 1999-09-10 EP EP99940424A patent/EP1114031B1/fr not_active Expired - Lifetime
- 1999-09-10 DK DK99940424T patent/DK1114031T3/da active
- 1999-09-10 EA EA200100202A patent/EA004674B1/ru unknown
- 1999-09-10 EE EEP200100166A patent/EE200100166A/xx unknown
- 1999-09-10 BR BR9913810-7A patent/BR9913810A/pt not_active Application Discontinuation
- 1999-09-10 OA OA1200100061A patent/OA11650A/en unknown
- 1999-09-10 HR HR20010201A patent/HRP20010201A2/hr not_active Application Discontinuation
- 1999-09-10 DE DE69925845T patent/DE69925845T2/de not_active Expired - Fee Related
- 1999-09-10 KR KR10-2001-7003402A patent/KR100428330B1/ko not_active Expired - Fee Related
- 1999-09-10 GE GEAP19995805A patent/GEP20033051B/en unknown
- 1999-09-10 SK SK354-2001A patent/SK3542001A3/sk unknown
- 1999-09-10 AU AU54401/99A patent/AU752566B2/en not_active Ceased
- 1999-09-13 DZ DZ990190A patent/DZ2890A1/fr active
- 1999-09-13 MA MA25765A patent/MA26688A1/fr unknown
- 1999-09-13 TN TNTNSN99171A patent/TNSN99171A1/fr unknown
- 1999-10-09 UA UA2001031790A patent/UA68390C2/uk unknown
2000
- 2000-09-10 CU CU20010050A patent/CU23082A3/es unknown
- 2000-10-10 US US09/685,380 patent/US6586448B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6310A patent/CR6310A/es unknown
- 2001-02-19 IL IL141505A patent/IL141505A/en unknown
- 2001-02-23 IS IS5859A patent/IS5859A/is unknown
- 2001-03-16 NO NO20011350A patent/NO318830B1/no unknown
- 2001-04-10 BG BG105428A patent/BG65125B1/bg unknown
2003
- 2003-06-27 US US10/607,640 patent/US6906082B2/en not_active Expired - Fee Related
2004
- 2004-08-18 JP JP2004238309A patent/JP2004339239A/ja active Pending
2005
- 2005-06-13 US US11/152,753 patent/US20050245570A1/en not_active Abandoned
2006
- 2006-01-26 IL IL173393A patent/IL173393A0/en unknown
- 2006-04-12 JP JP2006109338A patent/JP2006188542A/ja not_active Abandoned

Also Published As

Publication number	Publication date
DE69925845T2 (de)	2006-05-18
AP1346A (en)	2004-12-15
CN1318058A (zh)	2001-10-17
DE69925845D1 (en)	2005-07-21
JP2004339239A (ja)	2004-12-02
OA11650A (en)	2004-12-07
US6586448B1 (en)	2003-07-01
MA26688A1 (fr)	2004-12-20
JP2002526475A (ja)	2002-08-20
AU752566B2 (en)	2002-09-19
NO20011350D0 (no)	2001-03-16
GT199900150A (es)	2001-03-03
EP1114031A1 (fr)	2001-07-11
HN1999000154A (es)	2000-01-12
BR9913810A (pt)	2001-06-19
PE20001069A1 (es)	2000-10-19
PT1114031E (pt)	2005-09-30
IL173393A0 (en)	2006-06-11
NO20011350L (no)	2001-05-09
AP2001002101A0 (en)	2001-03-31
AU5440199A (en)	2000-04-10
JP2006188542A (ja)	2006-07-20
DK1114031T3 (da)	2005-09-12
EP1114031B1 (fr)	2005-06-15
KR100428330B1 (ko)	2004-04-28
ES2243069T3 (es)	2005-11-16
HUP0103506A2 (hu)	2002-01-28
ID28026A (id)	2001-05-03
PL347099A1 (en)	2002-03-25
GEP20033051B (en)	2003-08-25
CZ2001955A3 (cs)	2001-12-12
HUP0103506A3 (en)	2002-11-28
EA200100202A1 (ru)	2001-10-22
BG65125B1 (bg)	2007-03-30
KR20010085813A (ko)	2001-09-07
TWI242007B (en)	2005-10-21
YU16501A (sh)	2004-05-12
CA2344350C (fr)	2007-01-02
NO318830B1 (no)	2005-05-09
CR6310A (es)	2003-11-25
AR021481A1 (es)	2002-07-24
IL141505A (en)	2007-02-11
JP3626685B2 (ja)	2005-03-09
CU23082A3 (es)	2005-08-17
PA8481401A1 (es)	2002-02-21
CA2344350A1 (fr)	2000-03-30
US6197786B1 (en)	2001-03-06
EA004674B1 (ru)	2004-06-24
IL141505A0 (en)	2002-03-10
TNSN99171A1 (fr)	2005-11-10
CO5370678A1 (es)	2004-02-27
US20040092550A1 (en)	2004-05-13
CN1331858C (zh)	2007-08-15
MY130670A (en)	2007-07-31
US20050245570A1 (en)	2005-11-03
US6906082B2 (en)	2005-06-14
HK1040243A1 (zh)	2002-05-31
IS5859A (is)	2001-02-23
ATE297898T1 (de)	2005-07-15
SK3542001A3 (en)	2002-06-04
UA68390C2 (en)	2004-08-16
TR200100768T2 (tr)	2001-07-23
EE200100166A (et)	2002-06-17
NZ509840A (en)	2002-11-26
WO2000017164A1 (fr)	2000-03-30
BG105428A (en)	2002-01-31
HRP20010201A2 (en)	2002-04-30

Publication	Publication Date	Title
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2414A1 (fr)	2003-01-04	2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr)	2004-12-20	Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26490A1 (fr)	2004-12-20	Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2155A1 (fr)	2002-10-26	Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.